

## **Perrigo Company to Market Terbinafine Hydrochloride Tablets**

PRNewswire-FirstCall  
ALLEGAN, Mich.

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, InvaGen Pharmaceuticals, Inc., has received tentative approval from the U.S. Food and Drug Administration (FDA) on its ANDA for Terbinafine Hydrochloride Tablets, 250 mg (base). Final approval is subject to the expiration of any applicable periods of patent protection for the reference tested drug (Lamisil® Tablets 250 mg (base), Novartis Consumer Healthcare, Inc.) listed in the FDA's Orange Book, including pediatric exclusivity extension. The listed patent will expire on December 30, 2006, subject to an additional pediatric extension. Perrigo will market the products produced under InvaGen Pharmaceuticals' ANDA.

Annual sales for the brand are approximately \$750 million, according to NDC data.

The Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, United Kingdom, Mexico, Germany and China. Visit Perrigo on the Internet (<http://www.perrigo.com/> ).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. Please see the "Cautionary Note Regarding Forward-Looking Statements" on pages 33 - 41 of the Company's Form 10-K for the year ended June 25, 2005, as well as the Company's subsequent filings with the Securities and Exchange Commission, for a discussion of certain important factors that relate to forward-looking statements contained in this press release. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Perrigo Company

CONTACT: Arthur J. Shannon, Vice President, Investor Relations and Communication, +1-269-686-1709, [ajshannon@perrigo.com](mailto:ajshannon@perrigo.com) , or Ernest J. Schenk, Manager, Investor Relations and Communication, +1-269-673-9212,

eschenk@perrigo.com , both of Perrigo Company

Web site: <http://www.perrigo.com/>

---

<https://investor.perrigo.com/2006-08-07-Perrigo-Company-to-Market-Terbinafine-Hydrochloride-Tablets>